DX 8951

Known as: DX-8951

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.

2007

2007

A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane…

C. VerschraegenA. Kudelka R. D. de Jager
Cancer Chemotherapy and Pharmacology
2007
Corpus ID: 42904332

Background: DX-8951f is a water-soluble camptothecin derivative with greater in vivo and in vitro activity than topotecan or…